Zobrazeno 1 - 10
of 60
pro vyhledávání: '"Einar O Vik-Mo"'
Autor:
Inge C Olsen, Thomas Henry, Corina Silvia Rueegg, Asgeir S Jakola, Hanne Blakstad, Petter Brandal, Liv Cathrine Heggebø, Ida Maria Henriksen Borgen, Hillevi Rylander, Cecilie Kiserud, Tonje Haug Nordenmark, Taran Paulsen Hellebust, Morten Egeberg Evensen, Magnus Gustavsson, Christina Ramberg, Mette Sprauten, Henriette Magelssen, Janani Moorthy, Karin Andersson, Ingela Raunert, Cecilie Moe, Carin Granlund, Dorota Goplen, Jorunn Brekke, Tor-Christian Aase Johannessen, Tora Skeidsvoll Solheim, Kirsten Marienhagen, Øyvind Humberset, Per Bergström, Måns Agrup, Ludvig Dahl, Michael Gubanski, Helene Gojon, Carl-Johan Brahme, Isabelle Rydén, Einar O Vik-Mo, Hanne C. Lie, Lars Asphaug, Maziar Hervani, Ingrid Kristensen, Rolf J Ledal, Eskil Degsell, Katja Werlenius, Malin Blomstrand
Publikováno v:
BMJ Open, Vol 13, Iss 3 (2023)
Introduction The use of proton therapy increases globally despite a lack of randomised controlled trials demonstrating its efficacy and safety. Proton therapy enables sparing of non-neoplastic tissue from radiation. This is principally beneficial and
Externí odkaz:
https://doaj.org/article/a71f1463c05244a9a4ac7eb02407367a
Publikováno v:
PLoS ONE, Vol 9, Iss 12, p e114739 (2014)
There is a great potential for the development of new cell replacement strategies based on adult human neural stem-like cells. However, little is known about the hierarchy of cells and the unique molecular properties of stem- and progenitor cells of
Externí odkaz:
https://doaj.org/article/f153c6e39a624e258f9272084f6cc435
Autor:
Erlend Skaga, Cassia B. Trewin-Nybråten, Pitt Niehusmann, Tom Børge Johannesen, Kirsten Marienhagen, Leif Oltedal, Stephanie Schipman, Anne Jarstein Skjulsvik, Ole Solheim, Tora Skeidsvoll Solheim, Terje Sundstrøm, Einar O. Vik-Mo, Petter Brandal, Tor Ingebrigtsen
Publikováno v:
Acta Oncologica, Vol 63, Iss 1 (2024)
Background: Surveillance of incidence and survival of central nervous system tumors is essential to monitor disease burden and epidemiological changes, and to allocate health care resources. Here, we describe glioma incidence and survival trends by h
Externí odkaz:
https://doaj.org/article/2fa8de0ecb25480b99d6d0eb23fd7472
Autor:
Awais A. Mughal, Lili Zhang, Artem Fayzullin, Andres Server, Yuping Li, Yingxi Wu, Rainer Glass, Torstein Meling, Iver A. Langmoen, Trygve B. Leergaard, Einar O. Vik-Mo
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 20, Iss 7, Pp 643-656 (2018)
BACKGROUND: Widespread infiltration of tumor cells into surrounding brain parenchyma is a hallmark of malignant gliomas, but little data exist on the overall invasion pattern of tumor cells throughout the brain. METHODS: We have studied the invasive
Externí odkaz:
https://doaj.org/article/e7d8f0c670ea40aa9340e000e558579b
Autor:
Einar O. Vik-Mo, Alba Corell, Asgeir Store Jakola, Kristin Sjåvik, Gregor Tomasevic, Ole Solheim, Eduardo Erasmo Mendoza Mireles, Eirik Helseth, Mina Lundborg, Anja Smits, Rickard L. Sjöberg, Jon Ramm-Pettersen, Peter Milos, Ruby Mahesparan, Tomás Gómez Vecchio, Øystein Vesterli Tveiten, Sasha Gulati, Björn Sjögren, Øyvind Salvesen, Eddie de Dios, Lars Kjelsberg Pedersen, Margret Jensdottir, Bodil Karoline Ravn Munkvold, Henrietta Nittby Redebrandt, Klas Holmgren, Jiri Bartek, Maria Zetterling
Publikováno v:
Neuro-Oncology Practice
Background Early extensive surgery is a cornerstone in treatment of diffuse low-grade gliomas (DLGGs), and an additional survival benefit has been demonstrated from early radiochemotherapy in selected “high-risk” patients. Still, there are a numb
Autor:
Liv Cathrine Heggebø, Ida Maria Henriksen Borgen, Hillevi Rylander, Cecilie Kiserud, Tonje Haug Nordenmark, Taran Paulsen Hellebust, Morten Egeberg Evensen, Magnus Gustavsson, Christina Ramberg, Mette Sprauten, Henriette Magelssen, Hanne Blakstad, Janani Moorthy, Karin Andersson, Ingela Raunert, Thomas Henry, Cecilie Moe, Carin Granlund, Dorota Goplen, Jorunn Brekke, Tor-Christian Aase Johannessen, Tora Skeidsvoll Solheim, Kirsten Marienhagen, Øyvind Humberset, Per Bergström, Måns Agrup, Ludvig Dahl, Michael Gubanski, Helene Gojon, Carl-Johan Brahme, Isabelle Rydén, Asgeir S Jakola, Einar O Vik-Mo, Hanne C. Lie, Lars Asphaug, Maziar Hervani, Ingrid Kristensen, Corina Silvia Rueegg, Inge C Olsen, Rolf J Ledal, Eskil Degsell, Katja Werlenius, Malin Blomstrand, Petter Brandal
Publikováno v:
BMJ Open. 13:e070071
IntroductionThe use of proton therapy increases globally despite a lack of randomised controlled trials demonstrating its efficacy and safety. Proton therapy enables sparing of non-neoplastic tissue from radiation. This is principally beneficial and
Autor:
Iver A. Langmoen, Einar O. Vik-Mo, Luna Djirackor, Luis P. Kuschel, Pitt Niehusmann, Henning Leske, Jens Pahnke, Bernt J. Due-Tønnessen, Philipp Euskirchen, David Capper, Skarphedinn Halldorsson, Cecilie Sandberg
Publikováno v:
Neuro-oncology Advances
Background Brain tumor surgery must balance the benefit of maximal resection against the risk of inflicting severe damage. The impact of increased resection is diagnosis-specific. However, the precise diagnosis is typically uncertain at surgery due t
Autor:
Erlend Skaga, Evgeny Kulesskiy, Swapnil Potdar, Ioannis Panagopoulos, Francesca Micci, Iver A. Langmoen, Cecilie J. Sandberg, Einar O. Vik-Mo
Publikováno v:
Translational Oncology. 26:101535
Serum-free culturing of patient-derived glioblastoma biopsies enrich for glioblastoma stem cells (GSCs) and is recognized as a disease-relevant model system in glioblastoma (GBM). We hypothesized that the temozolomide (TMZ) drug sensitivity of patien
Autor:
Siri F. Svensson, José De Arcos, Omar Isam Darwish, Jorunn Fraser‐Green, Tryggve H. Storås, Sverre Holm, Einar O. Vik‐Mo, Ralph Sinkus, Kyrre E. Emblem
Publikováno v:
Journal of Magnetic Resonance Imaging. 53
Autor:
Zanina Grieg, Cecilie Sandberg, Iver A. Langmoen, Erlend Skaga, Ida Ø. Skaga, Einar O. Vik-Mo
Publikováno v:
Journal of Cancer Research and Clinical Oncology
Purpose Constructed from a theoretical framework, the coordinated undermining of survival paths in glioblastoma (GBM) is a combination of nine drugs approved for non-oncological indications (CUSP9; aprepitant, auranofin, captopril, celecoxib, disulfi